Abbott Laboratories is paying US$450 M in upfront and near-term cash payments for the exclusive rights to develop and commercialise Reata Pharmaceuticals’ bardoxolone methyl outside of the US, Japan and certain other Asian countries. The drug has completed Phase IIa trials for chronic kidney disease.